Submit Manuscript  

Article Details


Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus

[ Vol. 17 , Issue. 3 ]

Author(s):

Satoshi Ida*, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara and Kazuya Murata*   Pages 293 - 303 ( 11 )

Abstract:


Background: When considering the administration of glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, or metformin, it is important to understand their weight loss effect as well as the degree of muscle loss caused by each drug in clinical practice.

Objective: To comparatively examine the effects of GLP-1RAs and oral antidiabetic drugs, including SGLT2 inhibitors and metformin, on muscle mass and body weight in patients with type 2 diabetes via a network meta-analysis of randomized controlled trials.

Methods: We included randomized controlled trials evaluating the effects of antidiabetic drugs on muscle mass and body weight. Mean difference (MD) and 95% confidence intervals (CIs) were calculated using a random-effects network meta-analysis.

Results: Of the studies identified, 18 randomized controlled trials (1, 363 subjects) satisfied the eligibility criteria. In all studies, the effects of these drugs on fat-free mass (FFM) were evaluated. Therefore, FFM, which is used as an alternative index of muscle mass, was included in the study. Semaglutide (MD: -1.68, 95% CI: -2.84 to -0.52), dapagliflozin (-0.53, -0.93 to -0.13), and canagliflozin (-0.90, -1.73 to -0.07) showed a significant decrease in FFM compared with the placebo. Metformin did not show a significant decrease in FFM compared with the placebo. When compared with the placebo, semaglutide, dapagliflozin, ipragliflozin, and canagliflozin showed a significant weight loss.

Conclusion: Although semaglutide, dapaglifrozin, and canagliflozin have a large weight loss effect, it is important to pay attention to muscle loss because a decrease in FFM was observed.

Keywords:

Antidiabetic drugs, body weight, glucagon-like peptide-1 receptor agonists, muscle mass, network meta-analysis, type 2 diabetes mellitus.

Affiliation:

Department of Diabetes and Metabolism, Ise Red Cross Hospital, Mie, Department of Diabetes and Metabolism, Ise Red Cross Hospital, Mie, Department of Diabetes and Metabolism, Ise Red Cross Hospital, Mie, Department of Diabetes and Metabolism, Ise Red Cross Hospital, Mie, Department of Diabetes and Metabolism, Ise Red Cross Hospital, Mie, Department of Diabetes and Metabolism, Ise Red Cross Hospital, Mie, Department of Diabetes and Metabolism, Ise Red Cross Hospital, Mie, Department of Diabetes and Metabolism, Ise Red Cross Hospital, Mie



Read Full-Text article